)

Xeris Biopharma Holdings (XERS) investor relations material
Xeris Biopharma Holdings H.C. Wainwright 27th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Business performance and growth outlook
Achieved adjusted EBITDA positivity last year and maintains strong 85% gross margins, supporting self-funded growth.
Revenue growth is driven by three key products: Gvoke®, Keveyis®, and Recorlev®, with Recorlev® identified as the largest and fastest-growing.
Recorlev® targets a billion-dollar market opportunity, fueled by increased screening for hypercortisolemia and Cushing's syndrome.
Commercial footprint is scaling in line with market growth, with ongoing investments planned through 2027 to support expansion.
Capital deployment focuses on maximizing ROI, prioritizing Recorlev® and pipeline asset XP8121, leveraging strong revenue and margin profile.
Product pipeline and innovation
XP8121, a once-weekly subcutaneous levothyroxine, is phase 3-ready and targets patients with GI absorption issues, addressing a significant unmet need.
Phase 3 trial for XP8121 will be a one-year, non-inferiority study with at least 1,000 patients, aiming for robust clinical and payer-relevant data.
XP8121 is estimated as a $1–3 billion market opportunity, with innovation expected to drive payer acceptance due to unmet needs.
Gvoke® continues to grow in the diabetes market, focusing on education and guideline compliance, with long-term double-digit growth expected.
Keveyis® remains resilient despite generic competition, consistently adding new and returning patients in the ultra-rare disease segment.
Market dynamics and competitive positioning
Recorlev®'s unique mechanism of action allows for gradual cortisol reduction, differentiating it from competitors that block at the receptor level.
Increased screening and detection in the market are seen as positive, expanding the overall opportunity and not posing a significant threat.
Commercial investments are ongoing to support both short- and long-term growth, including sales, patient services, and reimbursement support.
Payer strategy for XP8121 includes targeting patients with multiple TSH tests out of range, leveraging clinical evidence to address reimbursement challenges.
The company leverages its technology and experience in drug-device combinations to support new product launches in endocrinology.
Next Xeris Biopharma Holdings earnings date

Next Xeris Biopharma Holdings earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage